AADI
Aadi Bioscience Inc
Aadi Bioscience Inc
$AADI Reports Promising Enrollment and Financial Results in Q1 2023 for Precision Cancer Therapy Development
Aadi Bioscience reported optimistic Q1 results and progress with its PRECISION 1 trial, a tumor-agnostic Phase 2 study of nab-sirolimus in treatment for solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes. The company's enrollment has been well-balanced, and the efficacy analysis is expected to be released later this year. Aadi also announced an ongoing Phase 2 trial for KRASG12C and plans to collaborate with Mirati Therapeutics. Overall, the company's focus on developing precision therapies for genetically defined cancers has shown progress, positioning itself as a fruitful investment opportunity for investors.
4mo ago
$AADIAadi Bioscience Inc
$AADI reports $15.2M sales & strong cash reserves, sets new R&D collaboration & welcomes new board member
Precision therapy-focused biopharmaceutical firm, Aadi Bioscience, has posted 2022 financials, reporting sales of $15.2m over a 10-month period and enough cash reserves to last until 2025. The company's collaboration with Mirati Therapeutics is due to start in Q2 2023, with the results of their PRECISION 1 trial expected around the same time. Dr. Mohammad Hirmand has been appointed to the Board of Directors, and CEO Scott Giacobello is confident about the future of Aadi Bioscience.
5mo ago
$AADI